Results 221 to 230 of about 3,072,312 (306)

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

Arthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf, Puja P. Khanna, Milan Petronijevic, Mamuka Lortkipanidze, Anand Patel, Kwabena Ayesu, Michael H. Pillinger, Atul Singhal, Joanna Sobierska, Jacquie Christie, Peter Traber, Rehan Azeem, Wesley DeHaan, Hugues Santin‐Janin, Bhavisha Desai, Alan Kivitz   +15 more
wiley   +1 more source

The Impact of Genetics on Pediatric Interstitial Lung Diseases: A Narrative Literature Review and Clinical Implications. [PDF]

Biomedicines
Mazzoni M, Lomuscio S, La Vecchia A, Terracciano R, Antonelli F, Vuilleumier P, Allegorico A.   +6 more
europepmc   +1 more source

Outcomes in progressive pulmonary fibrosis in systemic autoimmune rheumatic diseases: real‐world data from the ILD‐PRO Registry

Arthritis &Rheumatology, Accepted Article.
Objective We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease‐associated progressive pulmonary fibrosis (SARD‐PPF) and evaluated whether outcomes differed by SARD subtype. Methods The ILD‐PRO Registry is a prospective multicenter US registry of patients with PPF.
Sonali J Bracken, Jeremy M Weber, Megan L Neely, Aparna C Swaminathan, Scott M Palmer, Erin M Wilfong, Ann D Chauffe, Elizabeth R Volkmann   +7 more
wiley   +1 more source

Uncovering mirnomes of patients with interstitial lung diseases and an underlying autoimmune process. [PDF]

Respir Res
Sánchez-Pernaute O, Benítez Y, Vadillo Font C, Nieto MA, Cebrián L, López-Muñiz B, Romero-Bueno FI, Godoy H, Laporta R, Del Pozo Abeijón MV, Abásolo Alcázar L, Mínguez P, Rodríguez Nieto MJ.   +12 more
europepmc   +1 more source

Cancer in Systemic Sclerosis: Clinical Associations and Prognostic Impact From the EUSTAR Registry

Arthritis &Rheumatology, EarlyView.
Objective Cancer represents a major cause of death in systemic sclerosis (SSc). Established risk factors are limited to specific subsets, particularly early diffuse anti‐RNA polymerase III (POLR3)–positive disease, needing further exploration. Methods We performed a nested case‐control study within the European Scleroderma Trials and Research group ...
Antonio Tonutti, Francesca Motta, Liala Moschetti, Cosimo Bruni, Carina Mihai, Claudia Iannone, Maria Rosa Pellico, Stefano Stano, Stefano Erba, Claudia Barison, Eleonora Pazzi, Andrea Benini, Beatrice Moccaldi, Kurszán Jász Dávid, Ágnes Ágoston‐Szabó, Beatrice Gabrielli, Francesca Nava, Dóra Tari, Francesca Romana Di Ciommo, Yuri Sasaki, Gonçalo Boleto, Radim Bečvář, Alejandro Brigante, Britta Maurer, Massimiliano Limonta, Rahma A. Elziaty, Fabiola Atzeni, Lilian Maria López Núñez, Roberta Foti, Francesco Benvenuti, Brigitte Granel, Elena Rezus, Leila Caillault, Sophie Blaise, Cristiana Sieiro Santos, Fabio Cacciapaglia, Roberto Giacomelli, Rossella De Angelis, Serena Guiducci, Duygu Temiz Karadag, Gabriella Szűcs, Luca Idolazzi, Gábor Kumánovics, Florenzo Iannone, Maurizio Cutolo, Gianluca Moroncini, Valeria Riccieri, Nicoletta Del Papa, Elisabetta Zanatta, Oliver Distler, Masataka Kuwana, Carlo Selmi, Maria De Santis   +52 more
wiley   +1 more source

Correction: Understanding emotional and practical challenges of initiating oxygen therapy in pulmonary fibrosis: insights from a patient-centered survey

BMC Pulmonary Medicine
Marjolein Drent, Lian Trapman, Miranda Hennevelt-Leenen, Jan C. Grutters, Anne-Marie Russell   +4 more
doaj   +1 more source

Is Immunotherapy a Contraindication for Treating Lung Cancer Patients with Interstitial Lung Diseases? A Review of the Literature. [PDF]

J Clin Med
Pagliaro R, Della Monica P, D'Agnano V, Schiattarella A, D'Orologio A, Medusa PM, Stella GM, Colapietra F, Perrotta F, Bianco A, Di Domenico M, Scialò F.   +11 more
europepmc   +1 more source

Plasma Proteome Reflects Tissue Damage and Clinical Manifestations in Patients With Inflammatory Myopathies

Arthritis &Rheumatology, EarlyView.
Objective Tissue‐specific biomarkers that are reliable and associated with clinical manifestations of idiopathic inflammatory myopathy (IIM) are lacking. The blood circulation in individuals serves as a central conduit, allowing communication between tissues and facilitating clearance and recycling of tissue‐derived proteins.
Yue‐Bei Luo, Josefin Kenrick, Angeles S. Galindo‐Feria, Antonella Notarnicola, Ana Daniela Ulloa Navas, Irene Peralta‐Garcia, Orane Demuynck, Andrea Kemp, Valérie Leclair, Karin Lodin, Eveline Van Gompel, Lara Dani, Fabricio Espinosa‐Ortega, Maryam Dastmalchi, Leonid Padyukov, Charlotta Preger, María Bueno Álvez, Mathias Uhlén, Peter Nilsson, Fredrik Edfors, Lina‐Marcela Diaz‐Gallo, Elisa Pin, Ingrid E. Lundberg, Begum Horuluoglu   +23 more
wiley   +1 more source

Nerandomilast in Autoimmune-Associated Interstitial Lung Diseases: Translating Evidence from Progressive Pulmonary Fibrosis Studies. [PDF]

J Clin Med
Perrotta F, Mariniello DF, Stella GM, Pagliaro R, Scialò F, Liakouli V, Forte G, Ciccia F, Bianco A, D'Agnano V.   +9 more
europepmc   +1 more source

Expert Perspective: Toward Treat‐to‐Target Management in Adult Idiopathic Inflammatory Myopathies

Arthritis &Rheumatology, Accepted Article.
Treat‐to‐target (T2T) has transformed the management of several rheumatic diseases through predefined therapeutic goals, structured disease assessment, and timely treatment adjustment. Despite major advances in the understanding and treatment of idiopathic inflammatory myopathies (IIM), a formal T2T framework for adult IIM has not yet been established.
Shiri Keret, Nantakarn Pongtarakulpanit, Rohit Aggarwal   +2 more
wiley   +1 more source